The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.

Like Comment
Not available.

View the full article @ Haematologica

Get PDF with LibKey
Authors: Thai Hoa Tran, Jonathan V Nguyen, Adrian Stecula, Jon Akutagawa, Anthony V Moorman, Benjamin S Braun, Andrej Sali, Charles G Mullighan, Neil P Shah, Yunfeng Dai, Meenakshi Devidas, Kathryn G Roberts, Catherine C Smith, Mignon L Loh


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6584 Contributions
0 Following